Positive Phase 1 Results: Vaxxinity’s UB-312 Shows Promise in Parkinson’s Disease
By Daniella Parra
Vaxxinity (Nasdaq: VAXX) has revealed encouraging findings from the Phase 1b clinical trial of UB-312, their vaccine candidate targeting alpha-synuclein for the treatment and prevention of Parkinson’s disease (PD) and other synucleinopathies.
The study demonstrated that UB-312 was generally safe, well-tolerated, and elicited an immunogenic response in individuals with early-stage PD, the company said.
“These positive Phase 1 results demonstrate several important features necessary for an immunotherapy against Parkinson’s disease and other synucleinopathies to be successful, and represent a further proof-of-principle for Vaxxinity’s platform in chronic disease,” said Mei Mei Hu, CEO of Vaxxinity. “UB-312 was observed to safely break immune tolerance, inducing antibodies against toxic aggregated forms of alpha-synuclein.”
Contact:
Editor@Executives-edge.com
